Recent advance in hepatic insulin gene therapy

Citations of this article
Mendeley users who have this article in their library.


The development of type 1 diabetes results from the almost total destruction of insulin-producing pancreatic cells by autoimmune responses specific to cells. Standard insulin therapy may not maintain blood glucose concentrations within the relatively narrow range that occurs in the presence of normal pancreatic cells. We used a recombinant adeno-associated virus (rAAV) that expresses a single-chain insulin analogue (SIA), which possesses biologically active insulin activity without enzymatic conversion, under the control of hepatocyte-specific l-type pyruvate kinase (LPK) promoter, which regulates SIA expression in response to blood glucose levels. Here, we show that SIA produced from the gene construct rAAV-LPK-SIA caused remission of diabetes in streptozotocin-induced diabetic rats and autoimmune diabetic mice for a prolonged time without any apparent side effects. This new SIA gene therapy may have potential therapeutic value for the cure of autoimmune diabetes in humans. © 2004 Published by Elsevier Ireland Ltd.




Lee, H. C. (2004). Recent advance in hepatic insulin gene therapy. In Diabetes Research and Clinical Practice (Vol. 66). Elsevier Ireland Ltd.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free